Cannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection—A Narrative Review
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Worldwide, approximately 15 million people per year suffer from stroke. With about 5 million deaths, stroke is the second most common cause of death and a major cause of long-term disability. It is estimated that about 25% of people older than 85 years will develop stroke. Cannabis sativa and derived cannabinoids have been used for recreational and medical purposes for many centuries. However, due to the legal status in the past, research faced restrictions, and cannabis use was stigmatized for potential negative impacts on health. With the changes in legal status in many countries of the world, cannabis and cannabis-derived substances such as cannabinoids and terpenes have gained more interest in medical research. Several medical effects of cannabis have been scientifically proven, and potential risks identified. In the context of stroke, the role of cannabis is controversial. The negative impact of cannabis use on stroke has been reported through case reports and population-based studies. However, potential beneficial effects of specific cannabinoids are described in animal studies under certain conditions. In this narrative review, the existing body of evidence regarding the negative and positive impacts of cannabis use prior to stroke will be critically appraised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rigorous studies supporting these positive effects are missing [72].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [72]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There is a strong temporal link between cannabis exposure and the occurrence of stroke (i.e., ischemic), including chronic use and acute intoxication with onset ranging from “24 h” to “days before preceding the events” [72].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [72]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chapter 12: What does the Anthropocene hold for citizenship?
(2019) · edoc (University of Basel) · doi:10.1007/978-3 · Cited by 11,533
Easton, J. D., Saver, J. L., Albers, G. W., Alberts, M. J., Chaturvedi, S., Feldmann, E., Hatsukami, T. S., Higashida, R. T., Johnston, S. C., Kidwell, C. S., et al. (2009) · Stroke · doi:10.1161/strokeaha.108.192218 · Cited by 1,845
Johnston, L., Miech, R., & O'Malley, P. (2020) · doi:10.3998/2027.42/162579 · Cited by 1,611 · cited 2×
“In addition, the severity of stroke was pronounced in cannabis users, evidenced by significantly more hospitalizations in the cannabis users compared to nonusers [28,29].”
BackgroundZou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,343 · cited 6×
“AEA is produced in response to certain stimuli from glycerophospholipids by N-acyltransferase or N-acyl-phosphatidylethannolamine-specific phospholipase D (NAPE-PLD) [11].”
BackgroundInfluentialCannabinoids and the expanded endocannabinoid system in neurological disorders
Cristino, L., Bisogno, T., & Di Marzo, V. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-019-0284-z · Cited by 970 · cited 3×
“Both CB1 and CB2 receptor activation causes inhibition of adenylate cyclase activation by Gi or Go signaling processes, which results in an overall reduction in cyclic adenosine monophosphate (cAMP) production [6].”
BackgroundTriggering Myocardial Infarction by Marijuana
Mittleman, M. A., Lewis, R. A., Maclure, M., Sherwood, J. B., & Muller, J. E. (2001) · Circulation · doi:10.1161/01.cir.103.23.2805 · Cited by 767 · cited 2×
“Studies report that the hour immediately after smoking is a critical time point [36]; the risk of stroke increases significantly by about 4.8-fold [26].”
BackgroundResultInfluentialShen, M., Piser, T. M., Seybold, V. S., & Thayer, S. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04322.1996 · Cited by 604 · cited 1×
“FOR PEER REVIEW Research involving rat hippocampal cultures has demonstrated that activating CB1 can inhibit the release of glutamate presynaptically, thus protecting against glutamate-induced excitotoxicity [66].”
BackgroundCannabinoids and Neuroprotection in Global and Focal Cerebral Ischemia and in Neuronal Cultures
Nagayama, T., Sinor, A. D., Simon, R. P., Chen, J., Graham, S. H., Jin, K., & Greenberg, D. A. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-08-02987.1999 · Cited by 468 · cited 3×
“These channels are involved in the release of the neurotransmitter, glutamate, which has been shown to be related to neuronal death in several hypoxic and ischemic models [63].”
BackgroundMethodInfluentialCardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H., & Kunos, G. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.130 · Cited by 439 · cited 2×
“…potential sources for clot-for-mation-inducing ischemic Studies have found that the CB1 receptor activation may contribute to plaque development in blood vessels, while the CB2 receptor contributes to reduced plaque development, providing a protective effect [59]. stroke related to cannabis use.”
BackgroundThe Endocannabinoid System and its Modulation by Phytocannabinoids
Di Marzo, V., & Piscitelli, F. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0374-6 · Cited by 432
Research works printed but not linked: 1
- Amin, M.R., and Ali, D.W. (2019). Recent Advances in Cannabinoid Physiology and Pathology, Springer.
Cited by
Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits
Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01880-2 · Cited by 139
“Rigorous studies supporting these positive effects are missing [72].”
Multilayered neuroprotection by cannabinoids in neurodegenerative diseases
Hasbi, A., & George, S. R. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2024.100498 · Cited by 6
Exploring the Frontiers of Neuroinflammation: New Horizons in Research and Treatment
Rigillo, G., & Alboni, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46100692 · Cited by 4
“However, the same receptors are also implicated in vascular dysfunction, contributing to the risk of stroke [10].”
BackgroundStork, S. D. S., Mathias, K., Gava, F., Joaquim, L. D. S., dos Santos, D., Tiscoski, A. D. B., Bonfante, S., Strickert, Y. R., Machado, R. S., Martins, H. M., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01775-1 · Cited by 3
“By mitigating increased intestinal permeability, CBD can help reduce the potential for infection, widespread inflammation, and oxidative stress (Pellati et al. 2018; Iannotti et al. 2020; Viana et al. 2022; Carter et al. 2024).”
InfluentialAssociation Between Recreational Drug Use and Cardiovascular Events Post-Hospitalization in France
Mirailles, R., Delmas, C., Toupin, S., Bouleti, C., Trimaille, A., Schurtz, G., Piliero, N., Andrieu, S., Lattuca, B., Vasram, R. R., et al. (2026) · Circulation Population Health and Outcomes · doi:10.1161/circoutcomes.124.011905 · Cited by 2
Metadata
- Authors
- Carter, C., Laviolette, L., Bietar, B., Zhou, J., & Lehmann, C.
- Affiliations
- Dalhousie University (CA)
- Department of Anesthesia, Dalhousie University, Halifax, NS B3H 4R2, Canada
- Corresponding author
- Carter, Caroline
- Venue
- Current Issues in Molecular Biology
- Publisher
- MDPI AG
- Published
- 2024-04-04
- Volume
- 46
- Issue
- 4
- Pages
- 3122-3133
- ISSN
- 1467-3037 (ISSN-L)
- 1467-3045
- PMC
- PMC11048784
- OpenAlex
- W4393949197
- Cited by
- 13
- References
- 84
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 2
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Current Issues in Molecular Biology (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- cannabis, cannabinoids, stroke, Cannabis sativa, terpenes, stroke risk, neuroprotection, medical cannabis, recreational cannabis use, cannabis legalization
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection—A Narrative Review. https://app.cochat.ai/papers/10.3390/cimb46040196
- The paper
- Carter, C., Laviolette, L., Bietar, B., Zhou, J., & Lehmann, C. (2024). Cannabis, Cannabinoids, and Stroke: Increased Risk or Potential for Protection—A Narrative Review. Current Issues in Molecular Biology. https://doi.org/10.3390/cimb46040196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

![Figure 2 Mechanisms of action for neuroprotection by CB1 and/or CB2 receptor activation. Information from [49,63,67,68,69].](https://figures.cochat.ai/paper-figures/66d8379459bc403ea2e12fb92304b616/cannabis-cannabinoids-and-stroke-increased-risk-or-potential-for-protectiona-figure-2.jpg)